Expanded Lung Cancer Claim For Lilly’s Cyramza Faces US FDA Scrutiny

 
• By Sue Sutter

Oncologic Drugs Advisory Committee will consider whether a statistically significant benefit on progression-free survival, but no survival advantage, is enough to secure a first-line lung cancer indication for ramucirumab.

Lung cancer ( film x-ray of chest PA upright : show pleural effusion at left lung due to lung cancer ) ( 2 type of lung cancer : Non-small cell lung cancer , Small cell carcinoma )
Lilly seeks to move Cyramza's metastatic non-small cell lung cancer indication into the first-line setting. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers